Skip to content

Experimental Biological/Vaccine,Experimental Biological/Vaccine,Active Comparator Biological/Vaccine

7 trials

Sponsors

BioNet-Asia Co., Ltd. 19 Soi Udomsuk 37, Sukhumvit 103 Rd., Prakanong, Bangkok 10260 Thailand, BioNet-Asia Co., Ltd. 19 Soi Udomsuk 37, Sukhumvit 103 Road, Prakanong, Bangkok 10260, Thailand, Chulalongkorn University, BioNet-Asia Co., Ltd., Liaoning Cheng Biotechnology, Shenyang

Conditions

Healthy children Japanese encephalitis Japanese encephalitis vaccine Immunogenicity Booster Inactivated JE vaccineParticipants who recovered from COVID-19 COVID-19 Vaccine SARS-CoV-2 Antibody Cellular immunity Post COVID-19 intramuscular intradermalPertussis PertussisPertussis Whooping cough acellular Pertussis TdaPPertussis acellular pertussis vaccine (aP) and Tetanus Toxoid&#44Pertussis, Whooping cough Pertussis, Whooping coughPrevention of COVID-19 with SARS-CoV-2 mRNA vaccine platform, comparing the number of doses and interval after infection, in healthy Thai children aged 6 months to 4 years. SARS-CoV-2, mRNA vaccine, COVID-19 vaccine, Child, Infant, Immunogenicity, Reactogenicity

Phase 1

Phase 2

A phase II/III randomized, observer-blind, controlled study to demonstrate non-inferior immunogenicity of a combined Tetanus-diphtheria-acellular Pertussis vaccine as compared to Adacel® vaccine in healthy subjects aged 12-17 years
Active, not recruitingTCTR20150703002
BioNet-Asia Co., Ltd. 19 Soi Udomsuk 37, Sukhumvit 103 Road, Prakanong, Bangkok 10260, ThailandPertussis acellular pertussis vaccine (aP) and Tetanus Toxoid&#44
Start: 2015-07-06Updated: 2026-03-30
Immunogenicity of various recombinant acellular pertussis-containing vaccines in healthy adolescents
Active, not recruitingTCTR20181031001
Chulalongkorn UniversityPertussis Pertussis
Start: 2019-05-22Target: 450Updated: 2026-03-30
ChAdOx1 Vaccine Dose-Sparing Strategies in Post COVID-19 patients: A Randomized Controlled Trial
Active, not recruitingTCTR20211004005
National Research Council of Thailand (NRCT)Participants who recovered from COVID-19 COVID-19 Vaccine SARS-CoV-2 Antibody Cellular immunity Post COVID-19 intramuscular intradermal
Start: 2022-08-01Target: 360Updated: 2026-03-30
Safety and Immunogenicity of mRNA SARS-CoV-2 vaccine in healthy Thai children aged 6 months-4 years with or without previous SARS-CoV-2 infection (COVID-19)
Active, not recruitingTCTR20220927003
National Vaccine InstitutePrevention of COVID-19 with SARS-CoV-2 mRNA vaccine platform, comparing the number of doses and interval after infection, in healthy Thai children aged 6 months to 4 years. SARS-CoV-2, mRNA vaccine, COVID-19 vaccine, Child, Infant, Immunogenicity, Reactogenicity
Start: 2022-10-29Target: 120Updated: 2026-03-30

Phase 4

Related Papers